Prof. Dr. YUSUF YILMAZ

Alimentary pharmacology & therapeutics , cilt.51, ss.577, 2020 (SCI-Expanded)

Letter: a stepwise approach towards the screening of hepatic fibrosis in the general population.

Alimentary pharmacology & therapeutics , cilt.51, ss.669-670, 2020 (SCI-Expanded)

Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease.

Alkayyali T., Qutranji L., Kaya E., Bakir A., Yilmaz Y.

Acta diabetologica , 2020 (SCI-Expanded) Sürdürülebilir Kalkınma

NFS Is Not a Marker of Nonalcoholic Fatty Liver Disease Per Se: What Is the True Relationship With CAD Complexity?

Yılmaz Y., Eren F.

ANGIOLOGY , cilt.71, ss.83-84, 2020 (SCI-Expanded)

Arterial stiffness is associated independently with liver stiffness in biopsy-proven nonalcoholic fatty liver disease: a transient elastography study.

Bilgin B., Sunbul M., Kani H. T., Demirtas C., Keklikkiran C., Yilmaz Y.

European journal of gastroenterology & hepatology , cilt.32, ss.54-57, 2020 (SCI-Expanded)

Characterization of Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease and Normal Aminotransferase Levels.

Ulasoglu C., Enc F., Kaya E., Yilmaz Y.

Journal of gastrointestinal and liver diseases : JGLD , cilt.28, ss.427-431, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma

Potential clinical variants detected in mitochondrial DNA D-loop hypervariable region I of patients with non-alcoholic steatohepatitis

Hasturk B., Yilmaz Y., Eren F.

HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM , cilt.18, ss.463-475, 2019 (SCI-Expanded)

Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.

Tatar B., Köse Ş., Ergun N., Turken M., Onlen Y., Yılmaz Y., et al.

Revista da Associacao Medica Brasileira (1992) , cilt.65, ss.1470-1475, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma

Transient elastography for assessing severe hepatic fibrosis in diabetic patients with nonalcoholic fatty liver disease: definitions matter

Yilmaz Y., Eren F.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.31, sa.12, ss.1601-1602, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma

Comments on "The Effect of Laparoscopic Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease"

Yılmaz Y., Eren F.

SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES , cilt.29, sa.6, ss.548, 2019 (SCI-Expanded)

Hepatic fibrosis - and not steatosis - is the main determinant of arterial stiffness in non-alcoholic fatty liver disease

Yilmaz Y., Eren F.

ATHEROSCLEROSIS , cilt.290, ss.222-223, 2019 (SCI-Expanded)

Non-alcoholic fatty liver disease: A growing public health problem in Turkey

Kaya E., YILMAZ Y.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.30, sa.10, ss.865-871, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma

Evaluation of depression, anxiety and quality of life in hepatitis C patients who treated with direct acting antiviral agents

Kesen O., Kani H., Yanartaş Ö., Aykut U., Gök B., Gündüz F., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.30, sa.9, ss.801-806, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma

Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease

Younossi Z. M., Stepanova M., Ong J., Yılmaz Y., Duseja A., Eguchi Y., et al.

Clinical Gastroenterology and Hepatology , cilt.17, ss.1625, 2019 (SCI-Expanded)

Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Younossi Z., Tacke F., Arrese M., Chander Sharma B., Mostafa I., Bugianesi E., et al.

Hepatology , cilt.69, ss.2672-2682, 2019 (SCI-Expanded)

Liver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease

Dq S., Fang Zhoe Y., KANİ H. T., Chen Fei Z., Pei Wu Z., Hong Lei M., et al.

Journal Of Hepatology , cilt.70, ss.787, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma

Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study

DEMİR M., Deyneli O., YILMAZ Y.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.30, sa.3, ss.266-270, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma

Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates

Younossi Z., Stepanova M., Ong J. P., Jacobson I. M., Bugianesi E., Duseja A., et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY , cilt.17, sa.4, ss.748-758, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma

The optimal controlled attenuation parameter cut-offs in hepaticsteatosis grade differentiation by transient elastography(Fibroscan) in a sample of biopsy-proven non-alcoholic fatty liverdisease patients

Kaya E., BAKIR A., Sapmaz A. F., Kayyali T., Quatranji L., Çiftaslan A., et al.

Hepatology International , cilt.13, ss.196, 2019 (SCI-Expanded)

Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.31, sa.1, ss.43-46, 2019 (SCI-Expanded)

Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.

Yılmaz Y., Kani H. T., Demirtaş C., Kaya E., Sapmaz A., Qutranji L., et al.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology , cilt.30, ss.892-898, 2019 (SCI-Expanded)

THE SEQUENCE ANALYSIS OF NEW MITOCHONDRIALGENE, MOTS-C, IN PATIENTS WITH THE NON-ALCOHOLICSTEATOHEPATITIS

Önal O., Eren F., Yılmaz D., Göçmen T., Yılmaz Y.

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL , cilt.6, ss.135, 2018 (SCI-Expanded)

Nonalcoholic Fatty Liver Disease(NAFLD) and Alcoholic Fatty Lİver Disease(AFLD): The impact of Alcohol Comsumpt,on and Metabolic Syndrome on Mortality

Younossi Z., Maria S., Ong J., Yılmaz Y., Duseja A., Eguchi Y., et al.

Hepatology , cilt.68, ss.1, 2018 (SCI-Expanded)

Development of multiplex single base primer extension assay for the detection of potential association between MTNR1B gene polymorphisms and NASH

Yılmaz D., Eren F., Göçmen T., Yılmaz Y.

Journal Of Biotechnology , cilt.280, ss.76, 2018 (SCI-Expanded)

The association of fatty pancreas with subclinical atherosclerosis in nonalcoholic fatty liver disease

Ozturk K., Dogan T., Celikkanat S., Ozen A., Demirci H., Kurt O., et al.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.30, sa.4, ss.411-417, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma

The correlation between histopathologic steatosis/fibrosis and various non-invasive imagingand blood fibrosis indicators of overweight and obese children

Tutar E., Şahin Akkelle B., Kesici C. B., Yılmaz Y., Çelikel Ç., Ergelen R., et al.

Journal Of Pediatric Gastroenterology And Nutrition , cilt.66, 2018 (SCI-Expanded)

Transient elastography with controlled attenuation parameter in the assessment of hepatic steatosis and significant liver fibrosis in patients with scleroderma

Yılmaz Y., Kani H. T., Şahinkaya Y., Deliktaş İ., Mursaloğlu H. H., Aziziy M., et al.

Hepatology International , cilt.12, 2018 (SCI-Expanded)

Recommendation for treatment of hepatitis C virus infection

KAYMAKOĞLU S., Koksal I., KAYMAKOĞLU S., Tabak F., Akarca U. S., Akbulut A., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.28, 2017 (SCI-Expanded) Sürdürülebilir Kalkınma

Nonalcoholic steatohepatitis and gut microbiota: Future perspectives on probiotics in metabolic liver diseases

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.28, sa.5, ss.327-328, 2017 (SCI-Expanded)

The association of nonalcoholic fatty liver disease with genetic polymorphisms: A multicenter study

Uygun A., Ozturk K., Demirci H., Oztuna A., Eren F., Kozan S., et al.

European Journal of Gastroenterology and Hepatology , cilt.29, ss.441-447, 2017 (SCI-Expanded)

Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter

Kaya E., Demir D., ÖZEN ALAHDAB Y., YILMAZ Y.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.28, sa.11, ss.1264-1267, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma

Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis

ERGELEN R., YILMAZ Y., Asedov R., ÇELİKEL Ç., Akin H., BUĞDAYCI O., et al.

ABDOMINAL RADIOLOGY , cilt.41, sa.8, ss.1505-1510, 2016 (SCI-Expanded)

The role of active brown adipose tissue in human metabolism

Ozguven S., Ones T., Yilmaz Y., Turoglu H. T., Imeryuz N.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.43, sa.2, ss.355-361, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma

Is NAFLD different in absence of metabolic syndrome?

CLINICAL DILEMMAS IN NON-ALCOHOLIC FATTY LIVER DISEASE , ss.44-49, 2016 (SCI-Expanded)

Diagnostic Role of Colon Capsule Endoscopy in Patients with Optimal Colon Cleaning

Akyüz Ü., Yılmaz Y., Ince A. T., Kaya B., Pata C.

Gastroenterology Research and Practice , cilt.2016, 2016 (SCI-Expanded)

Nonalcoholic Steatohepatitis Score is an Independent Predictor of Right Ventricular Dysfunction in Patients with Nonalcoholic Fatty Liver Disease

Sünbül M., Kivrak T., Durmus E., Akin H., Aydin Y., Ergelen R., et al.

CARDIOVASCULAR THERAPEUTICS , cilt.33, ss.294-299, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease

Dincses E., YILMAZ Y.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.27, sa.10, ss.1149-1153, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease

Ozturk O., ÇOLAK Y., ŞENATEŞ E., YILMAZ Y., Ulasoglu C., Doganay L., et al.

WORLD JOURNAL OF GASTROENTEROLOGY , cilt.21, sa.26, ss.8096-8102, 2015 (SCI-Expanded)

Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease

ERGELEN R., Akyuz U., Aydin Y., EREN F., YILMAZ Y.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.27, sa.6, ss.667-671, 2015 (SCI-Expanded)

Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels

Akyuz U., Yesil A., YILMAZ Y.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY , cilt.50, sa.3, ss.341-346, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease

Subasi C. F., Aykut U. E., YILMAZ Y.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.27, sa.2, ss.137-141, 2015 (SCI-Expanded)

Can Enhanced Autophagy Be Associated with Human Longevity? Serum Levels of the Autophagy Biomarker Beclin-1 Are Increased in Healthy Centenarians

Emanuele E., Minoretti P., Sanchis-Gomar F., Pareja-Galeano H., YILMAZ Y., Garatachea N., et al.

REJUVENATION RESEARCH , cilt.17, sa.6, ss.518-524, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness.

Sünbül M., Agirbasli M., Durmus E., Kivrak T., Akin H., Aydin Y., et al.

Atherosclerosis , cilt.237, sa.2, ss.490-3, 2014 (SCI-Expanded)

No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects

Yonal O., EREN F., YILMAZ Y., ATUĞ Ö., Over H. H.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.25, sa.6, ss.639-643, 2014 (SCI-Expanded)

A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease

YILMAZ Y., Younossi Z. M.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.26, sa.11, ss.1292-1295, 2014 (SCI-Expanded)

ARE PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE AT INCREASED RISK OF ASTHMA? - RESULTS FROM A TURKISH CROSS-SECTIONAL STUDY

Tasli B., YILMAZ Y.

RESPIROLOGY , cilt.19, ss.189, 2014 (SCI-Expanded)

A comparison of FibroMeter (TM) NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease

Aykut U. E., Akyuz U., Yesil A., EREN F., Gerin F., ERGELEN R., et al.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY , cilt.49, sa.11, ss.1343-1348, 2014 (SCI-Expanded)

A Potential Treatment of Non-Alcoholic Fatty Liver Disease with SIRT1 Activators

ÇOLAK Y., Yesil A., MUTLU H. H., Caklili O. T., Ulasoglu C., ŞENATEŞ E., et al.

JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES , cilt.23, sa.3, ss.311-319, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis

Musso G., Gambino R., Tabibian J. H., Ekstedt M., Kechagias S., Hamaguchi M., et al.

PLOS MEDICINE , cilt.11, sa.7, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

Letter: gut microbiota modulation contributes to coffee's benefits for non-alcoholic fatty liver disease - authors' reply

Yesil A., Yilmaz Y.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS , cilt.39, sa.12, ss.1442, 2014 (SCI-Expanded)

Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease

YILMAZ Y., Senates E., Yesil A., ERGELEN R., ÇOLAK Y.

JOURNAL OF DIABETES AND ITS COMPLICATIONS , cilt.28, sa.3, ss.328-331, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy

YILMAZ Y., Yesil A., Gerin F., ERGELEN R., Akin H., ÇELİKEL Ç., et al.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY , cilt.49, sa.5, ss.611-616, 2014 (SCI-Expanded)

Gallstone Disease Does Not Predict Liver Histology in Nonalcoholic Fatty Liver Disease

YILMAZ Y., Ayyildiz T., Akin H., ÇOLAK Y., Ozturk O., Senates E., et al.

GUT AND LIVER , cilt.8, sa.3, ss.313-317, 2014 (SCI-Expanded)

Obesity-Associated Nonalcoholic Fatty Liver Disease

CLINICS IN LIVER DISEASE , cilt.18, sa.1, ss.19-32, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography

YILMAZ Y., ERGELEN R., Akin H., Imeryuz N.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.25, sa.11, ss.1330-1334, 2013 (SCI-Expanded)

Review article: coffee consumption, the metabolic syndrome and non-alcoholic fatty liver disease

Yesil A., Yilmaz Y.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS , cilt.38, sa.9, ss.1038-1044, 2013 (SCI-Expanded)

Biomarkers for Early Detection of Non-Alcoholic Steatohepatitis: Implications for Drug Development and Clinical Trials

CURRENT DRUG TARGETS , cilt.14, sa.11, ss.1357-1366, 2013 (SCI-Expanded)

Liver disease and malnutrition

Purnak T., YILMAZ Y.

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY , cilt.27, sa.4, ss.619-629, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

Assessment of endothelial function in patients with nonalcoholic fatty liver disease

Colak Y., Senates E., Yesil A., YILMAZ Y., Ozturk O., Doganay L., et al.

ENDOCRINE , cilt.43, sa.1, ss.100-107, 2013 (SCI-Expanded)

Letter: diagnostic accuracy of M30 levels for identifying patients with non-alcoholic steatohepatitis

ALIMENTARY PHARMACOLOGY & THERAPEUTICS , cilt.37, sa.2, ss.283, 2013 (SCI-Expanded)

Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back

YILMAZ Y., ÇOLAK Y., Kurt R., Senates E., EREN F.

TUMORI , cilt.99, sa.1, ss.10-16, 2013 (SCI-Expanded)

Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease

YILMAZ Y., Ozturk O., Alandab Y., Senates E., ÇOLAK Y., Doganay H. L., et al.

DIGESTIVE AND LIVER DISEASE , cilt.45, sa.1, ss.58-62, 2013 (SCI-Expanded)

Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis

CLINICA CHIMICA ACTA , cilt.414, ss.154-157, 2012 (SCI-Expanded)

Hepatic expression and serum levels of syndecan 1 (CD 138) in patients with nonalcoholic fatty liver disease

YILMAZ Y., EREN F., ÇOLAK Y., Senates E., ÇELİKEL Ç., Imeryuz N.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY , cilt.47, sa.12, ss.1488-1493, 2012 (SCI-Expanded)

Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?

ALIMENTARY PHARMACOLOGY & THERAPEUTICS , cilt.36, sa.9, ss.815-823, 2012 (SCI-Expanded)

Research update for articles published in EJCI in 2010

Adlbrecht C., Aigner E., Bellon J. M., Bouloukaki I., Bouzas-Mosquera A., Carrilho A. J. F., et al.

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION , cilt.42, sa.11, ss.1149-1164, 2012 (SCI-Expanded)

Serum proteomics for biomarker discovery in nonalcoholic fatty liver disease

CLINICA CHIMICA ACTA , cilt.413, ss.1190-1193, 2012 (SCI-Expanded)

Review article: non-alcoholic fatty liver disease and osteoporosis - clinical and molecular crosstalk

ALIMENTARY PHARMACOLOGY & THERAPEUTICS , cilt.36, sa.4, ss.345-352, 2012 (SCI-Expanded)

Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease

Eren F., Kurt R., Ermis F., Atuğ Ö., Imeryuz N., Yılmaz Y.

Clinical Biochemistry , cilt.45, ss.655-658, 2012 (SCI-Expanded)

Nonalcoholic Fatty Liver Disease: A Nutritional Approach

ÇOLAK Y., TUNCER İ., Senates E., Ozturk O., Doganay L., YILMAZ Y.

METABOLIC SYNDROME AND RELATED DISORDERS , cilt.10, sa.3, ss.161-166, 2012 (SCI-Expanded)

Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis

YILMAZ Y., Yonal O., Deyneli O., ÇELİKEL Ç., Kalayci C., DUMAN D.

ACTA GASTRO-ENTEROLOGICA BELGICA , cilt.75, sa.2, ss.240-244, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

Review article: fructose in non-alcoholic fatty liver disease

ALIMENTARY PHARMACOLOGY & THERAPEUTICS , cilt.35, ss.1135-1144, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome

YILMAZ Y., Senates E., Ayyildiz T., Colak Y., Tuncer I., Ovunc A. O. K., et al.

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION , cilt.42, sa.4, ss.411-418, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

Unconjugated hyperbilirubinemia and liver histology in patients with non-alcoholic fatty liver disease

Kurt R., YILMAZ Y.

CLINICAL BIOCHEMISTRY , cilt.45, sa.6, ss.515, 2012 (SCI-Expanded)

Circulating vaspin and its relationship with insulin sensitivity, adiponectin and liver histology in subjects with non-alcoholic steatohepatitis

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY , cilt.47, sa.4, ss.489-490, 2012 (SCI-Expanded)

Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology

Colak Y., Senates E., Ozturk O., YILMAZ Y., Zemheri E., Enc F. Y., et al.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.24, sa.3, ss.255-261, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

Is M65 really better than M30 as a biomarker of hepatic fibrosis?

YILMAZ Y., Kurt R.

HEPATOLOGY , cilt.55, sa.2, ss.654, 2012 (SCI-Expanded)

NAFLD in the Absence of Metabolic Syndrome: Different Epidemiology, Pathogenetic Mechanisms, Risk Factors for Disease Progression?

SEMINARS IN LIVER DISEASE , cilt.32, sa.1, ss.14-21, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

The impact of early percutaneous endoscopic gastrostomy placement on treatment completeness and nutritional status in locally advanced head and neck cancer patients receiving chemoradiotherapy

Atasoy B. M., Yonal O., Demirel B., DANE F., YILMAZ Y., Kalayci C., et al.

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY , cilt.269, sa.1, ss.275-282, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

Preliminary evidence of an association between the functional c-kit rs6554199 polymorphism and achalasia in a Turkish population

Alahdab Y., Eren F., Giral A., Gunduz F., Kedrah A. E., Atug O., et al.

NEUROGASTROENTEROLOGY AND MOTILITY , cilt.24, sa.1, ss.27-30, 2012 (SCI-Expanded)

Concentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: Association with liver fibrosis

ÇOLAK Y., Senates E., Coskunpinar E., Oltulu Y. M., Zemheri E., Ozturk O., et al.

DISEASE MARKERS , cilt.33, sa.2, ss.77-83, 2012 (SCI-Expanded)

Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: Association with ballooning degeneration

YILMAZ Y., Kurt R., EREN F., Imeryuz N.

SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION , cilt.71, sa.8, ss.631-636, 2011 (SCI-Expanded)

A Glance at the methods for detection of apoptosis qualitatively and quantitatively Apoptozun nitel ve nicel olarak tespitine yönelik metotlara ki{dotless}sa bir baki{dotless}ş

Ulukaya E., Acilan C., Ari F., Ikitimur E., Yılmaz Y.

Turkish Journal of Biochemistry , cilt.36, ss.261-269, 2011 (SCI-Expanded)

Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis

YILMAZ Y., EREN F., Ayyildiz T., Colak Y., Kurt R., Senates E., et al.

CLINICA CHIMICA ACTA , cilt.412, ss.2296-2299, 2011 (SCI-Expanded)

Cytokeratins in hepatitis

CLINICA CHIMICA ACTA , cilt.412, ss.2031-2036, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

Plasma Fibrinogen-Like Protein 2 Levels in Patients with Non-Alcoholic Fatty Liver Disease

Colak Y., Senates E., Ozturk O., YILMAZ Y., Coskunpinar E., Kahraman O. T., et al.

HEPATO-GASTROENTEROLOGY , cilt.58, sa.112, ss.2087-2090, 2011 (SCI-Expanded)

Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) are higher in ulcerative colitis and correlate with disease activity

Yilmaz Y., Yonal O., Eren F., Atug O., Hamzaoglu H. O.

Journal of Crohn's and Colitis , cilt.5, sa.5, ss.402-406, 2011 (SCI-Expanded)

Association Between The Presence of Brown Adipose Tissue and Nonalcoholic Fatty Liver Disease in Adult Humans

Yilmaz Y., Ones T., Purnak T., Kurt R., Ozguven S., Atug O., et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.38, 2011 (SCI-Expanded)

Association between the presence of brown adipose tissue and non-alcoholic fatty liver disease in adult humans.

Yilmaz Y., Ones T., Purnak T., Ozguven S., Kurt R., Atug O., et al.

Alimentary pharmacology & therapeutics , cilt.34, sa.3, ss.318-23, 2011 (SCI-Expanded)

Author's Reply; Noninvasive Tests of Fibrosis: To Get the Right Answers, We Need to Ask the Right Questions

YILMAZ Y., Kurt R.

HEPATITIS MONTHLY , cilt.11, sa.8, ss.669-670, 2011 (SCI-Expanded)

Multimarker Strategies for Detecting NASH and NASH-Related Fibrosis: Promises and Caveats

YILMAZ Y., Kurt R., EREN F.

OBESITY SURGERY , cilt.21, sa.8, ss.1316-1317, 2011 (SCI-Expanded)

Serum Levels of Hepcidin in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease

Senates E., YILMAZ Y., Colak Y., Ozturk O., Altunoz M. E., Kurt R., et al.

METABOLIC SYNDROME AND RELATED DISORDERS , cilt.9, sa.4, ss.287-290, 2011 (SCI-Expanded)

Apoptosis: why and how does it occur in biology?

ULUKAYA E., Acilan C., YILMAZ Y.

CELL BIOCHEMISTRY AND FUNCTION , cilt.29, sa.6, ss.468-480, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

Serum galectin-3 levels in patients with nonalcoholic fatty liver disease

YILMAZ Y., EREN F., Kurt R., Yonal O., Polat Z., Senates E., et al.

CLINICAL BIOCHEMISTRY , cilt.44, sa.12, ss.955-958, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease

YILMAZ Y., Kurt R., Gurdal A., ÖZEN ALAHDAB Y., Yonal O., Senates E., et al.

ATHEROSCLEROSIS , cilt.217, sa.1, ss.125-129, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

Authors' Reply: Noninvasive liver fibrosis assessment; Why does the APRI not work for Hepatitis B?

YILMAZ Y., Yonal O., Kurt R.

HEPATITIS MONTHLY , cilt.11, sa.7, ss.557, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

Reply to Aydin et al: "To what extent is it right to measure serum vaspin, obestatin, and apelin-36 levels without a protease inhibitor in nonalcoholic fatty liver disease?"

Yılmaz Y., Eren F.

Metabolism: Clinical and Experimental , cilt.60, 2011 (SCI-Expanded)

Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease

Aktas B., YILMAZ Y., EREN F., Yonal O., Kurt R., Alandab Y., et al.

METABOLISM-CLINICAL AND EXPERIMENTAL , cilt.60, sa.4, ss.544-549, 2011 (SCI-Expanded)

Kefir Improves the Efficacy and Tolerability of Triple Therapy in Eradicating Helicobacter pylori

Bekar O., YILMAZ Y., Gulten M.

JOURNAL OF MEDICINAL FOOD , cilt.14, sa.4, ss.344-347, 2011 (SCI-Expanded)

Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease

YILMAZ Y., Yonal O., Kurt R., Bayrak M., Aktas B., Ozdogan O.

HEPATITIS MONTHLY , cilt.11, sa.2, ss.103-107, 2011 (SCI-Expanded)

Toward a Biochemical Diagnosis of NASH: Insights From Pathophysiology For Distinguishing Simple Steatosis From Steatohepatitis

Yilmaz Y., Ulukaya E.

CURRENT MEDICINAL CHEMISTRY , cilt.18, sa.5, ss.725-732, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

Serum progranulin as an independent marker of liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease

Yılmaz Y., Eren F., Yonal O., Polat Z., Bacha M., Kurt R., et al.

Disease Markers , cilt.31, ss.205-210, 2011 (SCI-Expanded)

Serum zinc-α2-glycoprotein concentrations in patients with non-alcoholic fatty liver disease

Yılmaz Y., Yonal O., Eren F., Kurt R., Celikel C. A., Ozdogan O., et al.

Clinical Chemistry and Laboratory Medicine , cilt.49, ss.93-97, 2011 (SCI-Expanded)

Circulating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver disease

Yılmaz Y., Yonal O., Kurt R., Alahdab Y., Ozdogan O., Celikel C. A., et al.

Archives of Medical Research , cilt.42, ss.38-43, 2011 (SCI-Expanded)

Protective effect of the vasopressin agonist terlipressin in a rat model of contrast-induced nephropathy.

Ari E., Yılmaz Y., Kedrah A. E., Alahdab Y., Cakalagaoglu F., Arikan H., et al.

American journal of nephrology , cilt.33, sa.3, ss.269-76, 2011 (SCI-Expanded)

Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease

Yılmaz Y., Yonal O., Kurt R., Alahdab Y., Eren F., Ozdogan O., et al.

Scandinavian Journal of Gastroenterology , cilt.46, ss.91-97, 2011 (SCI-Expanded)

Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B

EREN F., YILMAZ Y., Kose S., Ozdemir F. T., Yonal O., Kurt R., et al.

CLINICA CHIMICA ACTA , cilt.411, ss.2029-2032, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma

Liver Enzymes and Cardiovascular Outcomes a New Research Agenda

YILMAZ Y., Kuri R., Kalayci C.

HEPATOLOGY , cilt.52, sa.6, ss.2242, 2010 (SCI-Expanded)

Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease

Yılmaz Y., Yonal O., Kurt R., Oral A. Y., Eren F., Ozdogan O., et al.

Scandinavian Journal of Clinical and Laboratory Investigation , cilt.70, ss.541-546, 2010 (SCI-Expanded)

Serum fetuin A/alpha 2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis

YILMAZ Y., Yonal O., Kurt R., ARI F., YILMAZTEPE ORAL A., ÇELİKEL Ç., et al.

ANNALS OF CLINICAL BIOCHEMISTRY , cilt.47, ss.549-553, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma

Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease

YILMAZ Y., Eren F., Yonal O., Kurt R., Aktas B., ÇELİKEL Ç., et al.

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION , cilt.40, sa.10, ss.887-892, 2010 (SCI-Expanded)

Apoptosis in nonalcoholic steatohepatitis with normal aminotransferase values: zooming in on cytokeratin 18 fragments

YILMAZ Y., Kurt R., Kalayci C.

BIOMARKERS IN MEDICINE , cilt.4, sa.5, ss.743-745, 2010 (SCI-Expanded)

Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis

YILMAZ Y., Alanhdab Y., Yonal O., Kurt R., Kedrah A. E., ÇELİKEL Ç., et al.

METABOLISM-CLINICAL AND EXPERIMENTAL , cilt.59, sa.9, ss.1327-1330, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma

Microalbuminuria and nonalcoholic fatty liver disease

Yılmaz Y., Alahdab Y. O., Yonal O., Imeryuz N., Kalayci C.

Metabolism: Clinical and Experimental , cilt.59, 2010 (SCI-Expanded)

The AGEs-RAGE axis and nonalcoholic steatohepatitis: the evidence mounts

JOURNAL OF GASTROENTEROLOGY , cilt.45, sa.7, ss.782-783, 2010 (SCI-Expanded)

Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: Association with liver fibrosis

YILMAZ Y., Kurt R., Yonal O., Polat N., ÇELİKEL Ç., Gurdal A., et al.

ATHEROSCLEROSIS , cilt.211, sa.1, ss.182-186, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma

Folic Acid and Vitamin B12 Supplementation Improves Coronary Flow Reserve in Elderly Subjects with Vitamin B12 Deficiency

Kurt R., YILMAZ Y., Ermis F., Besisik S. K., Polat N., Elitok A., et al.

ARCHIVES OF MEDICAL RESEARCH , cilt.41, sa.5, ss.369-372, 2010 (SCI-Expanded)

Cigarette Smoking Is Not Associated with Specific Histological Features or Severity of Nonalcoholic Fatty Liver Disease

YILMAZ Y., Yonai O., Kurt R., Avsar E.

HEPATOLOGY , cilt.52, sa.1, ss.391, 2010 (SCI-Expanded)

C-KIT Gene Polymorphism in Achalasia

Alahdab Y. O., EREN F., Gunduz F., Kedrah A. E., YILMAZ Y., Atug O., et al.

GASTROENTEROLOGY , cilt.138, sa.5, 2010 (SCI-Expanded)

Molecular Signatures of Nonalcoholic Fatty Liver Disease: The Present and Future

YILMAZ Y., ULUKAYA E.

HEPATOLOGY , cilt.51, sa.5, ss.1866, 2010 (SCI-Expanded)

Microalbuminuria in Nondiabetic Patients With Nonalcoholic Fatty Liver Disease: Association With Liver Fibrosis

YILMAZ Y., Alahdab Y. O., Yonal O., Kurt R., Kedrah A. E., Celikel C. A., et al.

GASTROENTEROLOGY , cilt.138, sa.5, 2010 (SCI-Expanded)

The Impact of Prophylactic Percutaneus Endoscopic Gastrostomy to Nutritional Status and Quality of Life in Locally Advanced Head and Neck Cancer Patients Receiving Chemoradiotherapy

Yonal O., Atasoy B. M., Demirel B., YILMAZ Y., Dane F., ABACIOGLU M. U., et al.

GASTROENTEROLOGY , cilt.138, sa.5, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma

Plasma prohepcidin levels in patients with chronic viral hepatitis: relationship with liver fibrosis

Olmez O. F., Gurel S., YILMAZ Y.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.22, sa.4, ss.461-465, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma

M30 levels and nonalcoholic steatohepatitis in polycystic ovary syndrome

Yılmaz Y., Kurt R.

Journal Of Clinical Endocrinology , cilt.0, sa.0, 2010 (SCI-Expanded)

Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients

Gul O. O., Tuncel E., YILMAZ Y., ULUKAYA E., Gul C. B., Kiyici S., et al.

METABOLISM-CLINICAL AND EXPERIMENTAL , cilt.59, sa.1, ss.64-69, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma

Metformin, hepatitis C, and insulin resistance: Sufficient evidence?

Yılmaz Y., Yonal O., Imeryuz N.

Hepatology , cilt.50, ss.2054-2055, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma

Systematic review: Caspase-cleaved fragments of cytokeratin 18 - The promises and challenges of a biomarker for chronic liver disease

Yılmaz Y.

Alimentary Pharmacology and Therapeutics , cilt.30, ss.1103-1109, 2009 (SCI-Expanded)

Familial Mediterranean Fever coexisting with celiac disease: Is there a link with long-term colchicine treatment?

Yilmaz Y., Baran B., Seniz N. B., Dolar E.

Journal of Gastrointestinal and Liver Diseases , cilt.18, ss.119-120, 2009 (SCI-Expanded)

Serial changes in circulating M30 antigen, a biomarker of apoptosis, in patients with acute coronary syndromes: Relationship with the severity of coronary artery disease

Senturk T., Aydinlar A., Yilmaz Y., Yilmaztepe Oral A., Ozdabakoglu O., Ulukaya E.

Coronary Artery Disease , cilt.20, ss.494-498, 2009 (SCI-Expanded)

Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: Association with insulin resistance

Yılmaz Y., Ulukaya E., Atuğ Ö., Dolar E.

European Journal of Gastroenterology and Hepatology , cilt.21, ss.1247-1251, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma

Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients

Arabul M., Gullulu M., Yilmaz Y., Eren M. A., Baran B., Gul C. B., et al.

Medical Science Monitor , cilt.15, 2009 (SCI-Expanded)

Human serum complement C3 and factor H in the syndrome of hemolysis, elevated liver enzymes, and low platelet count.

Ari E., YILMAZ Y., Gul A., ÖZEN ALAHDAB Y., Kedrah A. E., Macunluoglu B., et al.

American journal of reproductive immunology (New York, N.Y. : 1989) , cilt.62, sa.4, ss.238-42, 2009 (SCI-Expanded)

Non-alcoholic fatty liver disease and microalbuminuria in non-diabetic patients: Role of insulin resistance

Yılmaz Y., Alahdab Y., Özdoğan O. C., Dolar E.

Internal Medicine Journal , cilt.39, ss.709-710, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma

Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis

YILMAZ Y., Kedrah A. E., Ozdogan O.

WORLD JOURNAL OF GASTROENTEROLOGY , cilt.15, sa.35, ss.4387-4391, 2009 (SCI-Expanded)

Biomarkers for noninvasive biochemical diagnosis of nonalcoholic steatohepatitis: Tools or decorations?

YILMAZ Y., Dolar E.

WORLD JOURNAL OF GASTROENTEROLOGY , cilt.15, sa.34, ss.4346-4347, 2009 (SCI-Expanded)

"Defragmenting" the Noninvasive Diagnosis of Nonalcoholic Steatohepatitis: Hopes from Cytokeratin-18

HEPATOLOGY , cilt.50, sa.3, ss.990-991, 2009 (SCI-Expanded)

Commentary on "Cytokeratin 18, a Marker of Cell Death, is Increased in Children With Suspected Nonalcoholic Fatty Liver Disease"

YILMAZ Y., Dolar E., ULUKAYA E.

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION , cilt.49, sa.3, ss.371, 2009 (SCI-Expanded)

The quest for liver fibrosis biomarkers: Promises from the enhanced liver fibrosis panel and beyond

Yilmaz Y., Ulukaya E., Dolar E.

Hepatology , cilt.49, ss.1056-1057, 2009 (SCI-Expanded)

Serum M30 levels: A potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels

Yilmaz Y., Ulukaya E., Dolar E.

Hepatology , cilt.49, ss.697, 2009 (SCI-Expanded)

Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease

YILMAZ Y., ULUKAYA E., Gul O. O., Arabul M., Gul C. B., ATUĞ Ö., et al.

CLINICAL BIOCHEMISTRY , cilt.42, sa.9, ss.802-807, 2009 (SCI-Expanded)

Pegylated interferon/ribavirin-induced sudden sensorineural hearing loss in a patient with chronic hepatitis C

ATUĞ Ö., Akin H., YILMAZ Y., Sari M., Tozun N.

JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES , cilt.18, sa.2, ss.256, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma

Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C

Yilmaz Y., Dolar E., Ulukaya E., Akgoz S., Keskin M., Kiyici M., et al.

Medical Science Monitor , cilt.15, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma

Coronary artery anomalies in patients with syndrome X

Akgüllü Ç., Yilmaz Y., Yücel E., Kaderli A. A., Kumbay E., Ayndinlar A.

Anadolu Kardiyoloji Dergisi , cilt.9, ss.69, 2009 (SCI-Expanded)

Serum Levels of Adipokines in Patients with Chronic HCV Infection: Relationship with Steatosis and Fibrosis

Tiftikci A., ATUĞ Ö., YILMAZ Y., EREN F., Ozdemir F. T., Yapali S., et al.

ARCHIVES OF MEDICAL RESEARCH , cilt.40, sa.4, ss.294-298, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma

Dipeptidyl peptidase IV inhibitors: Therapeutic potential in nonalcoholic fatty liver disease

YILMAZ Y., ATUĞ Ö., Yonal O., DUMAN D., Ozdogan O., Imeryuz N., et al.

MEDICAL SCIENCE MONITOR , cilt.15, sa.4, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma

Baseline and salt-stimulated paraoxonase and arylesterase activities in patients with chronic liver disease: Relation to disease severity

Keskin M., Dolar E., Dirican M., Kiyici M., Yilmaz Y., Gurel S., et al.

Internal Medicine Journal , cilt.39, ss.243-248, 2009 (SCI-Expanded)

Liver Disease as a Risk Factor for Cognitive Decline and Dementia: an Under-Recognized Issue

YILMAZ Y., Ozdogan O.

HEPATOLOGY , cilt.49, sa.2, ss.698, 2009 (SCI-Expanded)

Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry

ULUKAYA E., YILMAZ Y., Moshkovskii S., Karpova M., Pyatnitskiy M., ATUĞ Ö., et al.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY , cilt.44, sa.12, ss.1471-1476, 2009 (SCI-Expanded)

Acute arsenic self-poisoning for suicidal purpose in a dentist: A case report

Yilmaz Y., Armagan E., Olmez O., Esen M., Alkis N., Dolar E.

Human and Experimental Toxicology , cilt.28, ss.63-65, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma

Small arterial elasticity predicts the extent of coronary artery disease: Relationship with serum uric acid

Fazlioǧlu M., Şentürk T., Kumbay E., Kaderli A. A., Yilmaz Y., Özdemir B., et al.

Atherosclerosis , cilt.202, ss.200-204, 2009 (SCI-Expanded)

Concomitant colitis in a patient with Behcet's disease

Yilmaz Y., Dolar E.

Journal of Gastrointestinal and Liver Diseases , cilt.17, sa.4, ss.481-483, 2008 (SCI-Expanded)

Predictive value of the modified early warning score in a turkish emergency department

Armagan E., Yilmaz Y., Olmez O. F., Simsek G., Gul C. B.

European Journal of Emergency Medicine , cilt.15, ss.338-340, 2008 (SCI-Expanded)

A "biomarker biopsy" for the diagnosis of NASH: Promises from CK-18 fragments

Yilmaz Y., Ulukaya E., Dolar E.

Obesity Surgery , cilt.18, ss.1507-1508, 2008 (SCI-Expanded)

Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease

Arabul M., Gullulu M., Yilmaz Y., Akdag I., Kahvecioglu S., Ali Eren M., et al.

Clinical Biochemistry , cilt.41, ss.1055-1058, 2008 (SCI-Expanded)

Effect of intensive statin therapy on arterial elasticity in patients with coronary artery disease

Akgullu C., Ozdemir B., Yilmaz Y., Kazazoglu A. R., Aydinlar A.

Acta Cardiologica , cilt.63, sa.4, ss.467-471, 2008 (SCI-Expanded)

The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-γ2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease

Catalano M., Cortelazzo A., Santi R., Contino L., Demicheli M., Yilmaz Y., et al.

Clinical Biochemistry , cilt.41, ss.981-985, 2008 (SCI-Expanded)

Helicobacter pylori: A role in schizophrenia?

Yilmaz Y., Gul C. B., Arabul M., Eren M. A.

Medical Science Monitor , cilt.14, 2008 (SCI-Expanded)

Apical ballooning syndrome: A metabolic form of cardiomyopathy?

Medical Science Monitor , cilt.14, 2008 (SCI-Expanded)

Urinary IL-18: A marker of contrast-induced nephropathy following percutaneous coronary intervention?

Bulent Gul C., Gullulu M., Oral B., Aydinlar A., Oz O., Budak F., et al.

Clinical Biochemistry , cilt.41, ss.544-547, 2008 (SCI-Expanded)

The -374T/A RAGE Polymorphism Protects Against Future Cardiac Events in Nondiabetic Patients with Coronary Artery Disease

Falcone C., Geroldi D., Buzzi M. P., Emanuele E., Yilmaz Y., Fontana J. M., et al.

Archives of Medical Research , cilt.39, ss.320-325, 2008 (SCI-Expanded)

Acute myocardial infarction, ischemic cerebrovascular disease and variceal bleeding due to portal vein thrombosis in a patient with hereditary thrombophilia

Baran B., Yilmaz Y., Algin O., Keskin M., Kiyici M., Kocamaz G., et al.

Blood Coagulation and Fibrinolysis , cilt.19, ss.243-246, 2008 (SCI-Expanded)

Psychopathology in the context of obesity: The adiponectin hypothesis

ERGENÇ İ., Gozaydinoglu B., KEKLİKKİRAN C., YILMAZ Y.

Medical Hypotheses , cilt.70, ss.902-903, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma

Clinical value of the malnutrition-inflammation-atherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with end-stage renal disease: A 5-year prospective study

Akdag I., Yilmaz Y., Kahvecioglu S., Bolca N., Ercan I., Ersoy A., et al.

Nephron - Clinical Practice , cilt.108, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma

The LPA gene C93T polymorphism influences plasma lipoprotein(a) levels and is independently associated with susceptibility to peripheral arterial disease

Catalano M., Cortelazzo A., Yilmaz Y., Perilli E., Carzaniga G., Emanuele E.

Clinica Chimica Acta , cilt.387, ss.109-112, 2008 (SCI-Expanded)

Evaluation of leukocyte esterase and nitrite strip tests to detect spontaneous bacterial peritonitis in cirrhotic patients

Torun S., Dolar E., Yilmaz Y., Keskin M., Kiyici M., Sinirtas M., et al.

World Journal of Gastroenterology , cilt.13, ss.6027-6030, 2007 (SCI-Expanded)

Clinical significance of activity of ALT enzyme in patients with hepatitis C virus

Akkaya O., Kiyici M., Yilmaz Y., Ulukaya E., Yerci O.

World Journal of Gastroenterology , cilt.13, ss.5481-5485, 2007 (SCI-Expanded)

Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis

Yilmaz Y., Dolar E., Ulukaya E., Akgoz S., Keskin M., Kiyici M., et al.

World Journal of Gastroenterology , cilt.13, ss.837-844, 2007 (SCI-Expanded)

Diğer Dergilerde Yayınlanan Makaleler

Optimal testing strategies for incidental anti-mitochondrial M2 antibody-positive patients

Ergenc I., Gozaydinoglu B., Keklikkiran C., YILMAZ Y.

Hepatology Forum , cilt.5, sa.3, ss.165-166, 2024 (Scopus)

Predicting fibrosis progression in non-alcoholic fatty liver disease patients using the FAST Score: A paired biopsy study

Sariyar N., KANİ H. T., ÇELİKEL Ç., YILMAZ Y.

Hepatology Forum , cilt.5, sa.1, ss.33-36, 2024 (Scopus)

Addressing the looming epidemic of metabolic dysfunction-associated steatotic liver disease in Pakistan: A call for action

Kamani L., Rahat A., YILMAZ Y.

Hepatology Forum , cilt.5, sa.1, ss.1-2, 2024 (Scopus)

Vibration-controlled transient elastography for non-invasive screening of liver fibrosis and steatosis in Turkish patients with psoriasis: A cross-sectional study

Aksoy A. N., Hanci B., Baskent M. F., Umutlu E. G., Kumas E. N., Emanet S. U., et al.

Hepatology Forum , cilt.5, sa.1, ss.29-32, 2024 (Scopus)

Prevalence, determinants, and fibrosis risk stratification of metabolic-associated fatty liver disease in a Turkish primary care setting: A retrospective study.

Arslan A. Y., Celik S., Amin F., Caylak I., Kesapli I., Kilic I. B., et al.

Hepatology forum , cilt.5, sa.2, ss.63-67, 2023 (ESCI) Sürdürülebilir Kalkınma

The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients

Hepatology forum , cilt.4, sa.2, ss.69-73, 2023 (Hakemli Dergi)

TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease

Yılmaz Y., Zeybel M., Adalı G., Coşar A., Sertesen E., Sümer H., et al.

Hepatology forum , cilt.4, sa.1, ss.1-32, 2023 (Hakemli Dergi)

The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease

YILMAZ Y., Kaya E.

HEPATOLOGY FORUM , cilt.4, sa.2, 2023 (ESCI)

Chronotype preference, sleep quality, and night-eating behaviors in patients with metabolic dysfunction-associated steatotic liver disease: Assessing the relationship with disease severity and fibrosis

Sakallı Kani A., Ozercan A., Kani H. T., Eren F., Sayar K., Yılmaz Y.

Hepatology Forum , cilt.4, sa.3, ss.123-128, 2023 (Scopus) Sürdürülebilir Kalkınma

Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease

Eris T., Hassan M., Hikal Y., Sawah E., Daneshgar F., Teker A. G., et al.

HEPATOLOGY FORUM , cilt.4, sa.1, ss.7-13, 2023 (ESCI)

Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan

Yesil E. E., Yılmaz Y., Yesil A., Mese M., Kaya E., Bakir E. A.

HEPATOLOGY FORUM , cilt.4, sa.1, ss.14-18, 2023 (ESCI)

The heated debate over NAFLD renaming: An ongoing saga

DEMİRTAŞ C. Ö., YILMAZ Y.

Hepatology Forum , cilt.4, sa.3, ss.89-91, 2023 (Scopus)

Insidious danger for young adults: Metabolic (dysfunction)associated fatty liver disease

Kaya E., YILMAZ Y.

HEPATOLOGY FORUM , cilt.3, sa.2, ss.39-40, 2022 (ESCI)

Prevention of hepatocellular carcinoma and surveillance of high risk patients

Kaya E., Mazzolini G. D., YILMAZ Y., CANBAY A.

Hepatology Forum , cilt.3, ss.33-38, 2022 (ESCI) Sürdürülebilir Kalkınma

Demographic Characteristics and Transmission Risk Factors of Patients with Hepatitis C Virus in Turkey: The EPI-C, A Multicenter and Cross-sectional Trial

TABAK F., ŞİRİN G., DEMİR M., ALADAĞ M., SÜMER Ş., KURTARAN B., et al.

Viral Hepatitis Journal , cilt.27, sa.3, ss.109-117, 2021 (ESCI) Sürdürülebilir Kalkınma

The prevalence of metabolic-associated fatty liver disease in the Turkish population: A multicenter study

YILMAZ Y., YILMAZ N., ATEŞ F., KARAKAYA F., GÖKCAN H., KAYA E., et al.

Hepatology Forum , cilt.2, sa.2, ss.37-42, 2021 (ESCI)

Comparison of aerobic and combined aerobic and whole-body vibration training effects on physical fitness in non-alcoholic fatty liver patients

Saldiran T. C., Mutluay F. K., Yagci İ., Yilmaz Y.

COMPARATIVE EXERCISE PHYSIOLOGY , cilt.17, sa.4, ss.393-401, 2021 (ESCI)

High incidence of hepatitis B core antibody positivity in metabolic-associated fatty liver disease-related cirrhosis

ERGENÇ İ., GÖKÇEN P., ADALI G., Kani H. T., Demirtaş C. Ö., Gündüz F., et al.

Hepatology Forum , cilt.1, sa.2, ss.20-25, 2021 (ESCI) Sürdürülebilir Kalkınma

The clinical and histological characteristics of patients with biopsy-proven non-alcoholic fatty liver disease in the absence of insulin resistance

DEMİRTAŞ C. Ö., SAPMAZ A., GÜREL B. A., KIZMAZ H., ULU T., KARAKETİR Ş. G., et al.

Hepatology Forum , cilt.1, sa.3, ss.101-108, 2020 (Hakemli Dergi) Sürdürülebilir Kalkınma

Metabolic-associated Fatty Liver Disease: Time to integrate ground-breaking new terminology to our clinical practice?

Hepatology Forum , cilt.1, sa.3, ss.79-81, 2020 (Hakemli Dergi)

Regular coffee intake improves liver enzyme levels and liver histology in patients with chronic alcohol consumption, non-alcoholic fatty liver and non-alcoholic steatohepatitis: Report of 259 cases

DEĞERTEKİN M. B., TÖZÜN A. N., Söylemez A. G., Gurtay E., Bozkurt U., YILMAZ Y., et al.

Hepatology Forum , cilt.1, sa.3, ss.88-96, 2020 (Hakemli Dergi)

The utility of noninvasive scores in non-alcoholic fatty liver disease patients with normal and elevated serum transaminases

Kaya E., Bakır A., Eren F., Yılmaz Y.

Hepatology Forum , cilt.1, sa.1, ss.8-13, 2020 (Hakemli Dergi)

The comparison of resting metabolic rate betweenbiopsy-proven non-alcoholic steatohepatitis andnon-alcoholic fatty liver patients

KENGER E. B., GÜVELİ H., Ergun C., Kaya E., YILMAZ Y.

Hepatology Forum , cilt.1, sa.1, ss.14-19, 2020 (Hakemli Dergi)

Prevalence of fatty liver disease in patients with inflammatory bowel disease: a transient elastography study on the basis of a controlled attenuation parameter

Kani H. T., Deliktas I., YILMAZ Y.

MARMARA MEDICAL JOURNAL , cilt.32, sa.2, ss.68-70, 2019 (ESCI)

Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome?

Yılmaz Y.

World Journal of Hepatology , cilt.4, ss.332-334, 2012 (Scopus)

A Glance at the methods for detection of apoptosis qualitatively and quantitatively

Ulukaya E., Açılan C., Arı F., Elif İlkay İ., Yılmaz Y.

A Glance at the methods for detection of apoptosis qualitatively and quantitatively , cilt.36, ss.261-269, 2011 (Hakemli Dergi)

Liver function tests: Association with cardiovascular outcomes

Yılmaz Y.

World Journal of Hepatology , cilt.2, ss.143-145, 2010 (Scopus) Sürdürülebilir Kalkınma

Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease Experience Significant Disease Burden and Stigma

Younossi Z., YILMAZ Y., Fan J., Zheng M., ALSWAT K. A., ALQAHTANI S., et al.

American Diabetes Association (ADA) 2024 Annual Congress, Amerika Birleşik Devletleri, 15 Haziran 2024, cilt.73, ss.1414

Clinical and biochemical characteristics of a Danish and Turkish cohort of incident and prevalent patients with primary biliary cholangitis

Eruzun H., Bossen L., TURAN D., Ergenç İ., HARPUT Z. N., GÜNEŞ AYDEMİR N., et al.

EASL Congress 2024, Milan, İtalya, 05 Haziran 2024, cilt.80, ss.723

Spleen stiffness measurement improves non-invasive prediction of clinically significant portal hypertension in primary biliary cholangitis

Francesca Manfredi G., Ergenç İ., Cittone M., Degasperi E., Neglia M. C., Bertetto R., et al.

EASL Congress 2024, Milan, İtalya, 05 Haziran 2024, cilt.80, ss.329

Fatigue is an Important Driver of Work Productivity Loss and Impairment of Patient-Reported Outcomes (PROs) among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Younossi Z., YILMAZ Y., Yu M., Isakov V., Fernández M. I. C., Wong V. W., et al.

EASL Congress 2024, Milan, İtalya, 05 Haziran 2024, cilt.80, ss.643

Prevalence and predictors of clinically significant pruritus in patients with non-alcoholic fatty liver disease (NAFLD): data from the global NASH registry™ (GNR™)

Annual Meeting of the Association for the Study of Liver Diseases (AASLD) Meeting 2023, Boston, Amerika Birleşik Devletleri, 10 Kasım 2023, cilt.78, ss.863

THE GLOBAL SURVEY OF DISEASE BURDEN AND STIGMA AMONG PATIENTS WITH NAFLD AND THEIR HEALTHCARE PROVIDERS

Annual Meeting of the Association for the Study of Liver Diseases (AASLD) Meeting 2023, Boston, Amerika Birleşik Devletleri, 10 Kasım 2023, cilt.78, ss.1050-1056

A GLOBAL SURVEY OF PHYSICIAN KNOWLEDGE ABOUT MANAGEMENT OF CHRONIC HEPATITIS C

American Association for the Study of Liver Diseases (AASLD) Meeting 2023, Boston, Amerika Birleşik Devletleri, 10 Kasım 2023, cilt.78, ss.671

Stigma in NAFLD and NASH: a global survey of patients and providers

International Liver Congress (EASL) 2023, Viyana, Avusturya, 01 Haziran 2023, cilt.78, ss.627-628

STIGMA IS A PREDICTOR OF IMPAIRMENT OF HEALTH RELATED QUALITY OF LIFE AMONG PATIENTS WITH NAFLD

Annual Meeting of the Association for the Study of Liver Diseases (AASLD) Meeting 2023, Boston, Amerika Birleşik Devletleri, 10 Kasım 2023, cilt.78, ss.1768-1774

Transient elastography measurements of spleen stiffness are associated with treatment response to ursodeoxycholic acid in primary biliary cholangitis

ERGENÇ İ., YAPICI H., KEKLİKKIRAN Ç., YILMAZ Y.

International Liver Congress (EASL) 2023, Avusturya, 21 - 24 Haziran 2023, cilt.78, ss.389-390

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS ASSOCIATED WITH SIGNIFICANT IMPAIRMENT OF WORK PRODUCTIVITY: DATA FROM THE GLOBAL NASH REGISTRY™

Younossi Z., YILMAZ Y., Yu M., Wong V., Fernandez M., Isakov V., et al.

cilt.77

Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease and type 2 diabetes

Pennisi G., Enea M., Falco V., Aithal G., Palaniyappan N., YILMAZ Y., et al.

55th A.I.S.F. - Italian Association for the Study of the Liver - Annual Meeting 2023, Milan, İtalya, 14 Mart 2023, cilt.55, ss.12-15 Sürdürülebilir Kalkınma

CLINICAL AND PATIENT-REPORTED OUTCOME (PRO) PROFILE OF PATIENTS WITH HEPATITIS B VIRAL (HBV) INFECTION FROM THE GLOBAL LIVER REGISTRY (TM) (GLR (TM))

Annual Meeting of the Association for the Study of Liver Diseases (AASLD) Meeting 2022, Washington, Kiribati, 04 Kasım 2022, cilt.76, ss.287-288

DEPRESSION AND EMOTIONAL DISTRESS IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY

Younossi Z. M., Stepanova M., Fernandez M. I. C., YILMAZ Y., Yu M., El Kassas M., et al.

Annual Meeting of the Association for the Study of Liver Diseases (AASLD) Meeting 2022, Washington, Kiribati, 04 Ekim 2022, cilt.76, ss.1049-1051

REAL-WORLD EVIDENCE ON NON-INVASIVE TESTS AND ASSOCIATED CUT-OFFS USED TO ASSESS FIBROSIS IN ROUTINE CLINICAL PRACTICE

Lazarus J. V., YILMAZ Y.

Annual Meeting of the Association for the Study of Liver Diseases (AASLD) Meeting 2022, Washington, Kiribati, 04 Kasım 2022, cilt.76, ss.818-820

Lean non-alcoholic fatty liver disease patients from the global NASH registry

EASL, Londrina, Brezilya, 22 Haziran 2022

Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease

EASL, Londrina, Brezilya, 22 Haziran 2022

Multimodality assessment of hepatic fibrosis: ranked paired reading and artificial intelligence identifies fibrosis improvement with aramchol missed by conventional staging

EASL, Londrina, Brezilya, 22 Haziran 2022

ANALYSIS OF THE EFFICACY OF A HIGHER DAILY ARAMCHOL DOSE ON FIBROSIS IMPROVEMENT IN THE ARMOR STUDY OPEN LABEL PART

Gorfine T., Ratziu V., YILMAZ Y., Friedman S. L., Hayardeny L., Kadosh S., et al.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Amerika Birleşik Devletleri, 12 Kasım 2021

Development and validation of Agile 4 and Agile 3+: Novel FibroScan based scores for the diagnosis of cirrhosis and advanced fibrosis in patients with non-alcoholic fatty liver disease

French Hepatology congress (AFEF) 29 Eylül 2021-02 Ekim 2021, Biarritz, Fransa, 07 Temmuz 2021

The Impact of COVID-19 Pandemic on Patients with Chronic Liver Disease (CLD): Data from the Global Registry

YOUNOSSI Z. M., YILMAZ Y., El Kassas M., Duseja A. K., Saeed H., Gammal E., et al.

International Liver Congress (EASL), Roma, İtalya, 23 Haziran 2021, cilt.75, ss.655 Sürdürülebilir Kalkınma

The global non-alcoholic fatty liver disease (NAFLD) preparedness index: are countries ready to tackle the challenge?

Lazarus J., Mark H., Palayew A., Patrizia C., Colombo M., Ekstedt M., et al.

International Liver Congress, ELECTR NETWORK, 23 - 26 Haziran 2021, cilt.75

Individual patient data meta-analysis of the diagnostic performance of single and sequentially combined non-invasive tests in detecting advanced fibrosis

International Liver Congress (EASL), Roma, İtalya, 23 Haziran 2021, cilt.75, ss.259-260

Development and validation of Agile 3+: novel FibroScan based score for the diagnosis of advanced fibrosis in patients with nonalcoholic fatty liver disease

YOUNOSSI Z. M., Harrison S. A., Newsome P. N., CHAN W. K., YILMAZ Y., Ledinghen V. d., et al.

International Liver Congress (EASL), Roma, İtalya, 23 - 26 Haziran 2021, cilt.75, ss.257

A GLOBAL SURVEY OF PHYSICIANS KNOWLEDGE ABOUT NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

Digestive Disease Week, Amerika Birleşik Devletleri, 21 Mayıs 2021, cilt.160, ss.830

CLINICAL PRESENTATION OF LEAN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) ACROSS THE WORLD: DATA FROM THE GLOBAL NASH REGISTRY

Digestive Disease Week, Amerika Birleşik Devletleri, 21 Mayıs 2021, cilt.160, ss.771-772

CLINICAL PRESENTATION AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC VIRAL HEPATITIS: DATA FROM THE GLOBAL LIVER REGISTRY (TM)

Digestive Disease Week, Amerika Birleşik Devletleri, 21 Mayıs 2021, cilt.160, ss.821-822 Sürdürülebilir Kalkınma

RESOLVE-IT PHASE 3 TRIAL OF ELAFIBRANOR IN NASH: FINAL RESULTS OF THE WEEK 72 INTERIM SURROGATE EFFICACY ANALYSIS

Harrison S. A., Ratziu V., Bedossa P., Dufour J., Kruger F., Schattenberg J. M., et al.

AASLD The Liver Meeting, Virginia, Amerika Birleşik Devletleri, 13 - 16 Kasım 2020, ss.23 Sürdürülebilir Kalkınma

PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C: DATA FROM THE GLOBAL LIVER REGISTRY (TM)

Yu M., El Kassas M., Lam B. P., Esmat G., Femandez M. C., Ferret M. A. B., et al.

Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 Kasım 2020, cilt.72 Sürdürülebilir Kalkınma

CLINICAL AND PATIENT-REPORTED OUTCOMES DATA OF NON-ALCOHOLIC FATTY LIVER DISEASE: LONGITUDINAL DATA FROM THE GLOBAL NASH REGISTRY (TM)

Younossi Z. M., YILMAZ Y., Yu M., Wong V. W., Castellanos Fernandez M., Isakov V. A., et al.

Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 Kasım 2020, cilt.72

THE IMPACT OF CHRONIC HEPATITIS B ON PATIENT-REPORTED OUTCOMES FROM THE GLOBAL LIVER REGISTRY (TM)

YILMAZ Y., Yu M., Lam B. P., Ferret M. A. B., Papatheodoridis G., Chan W. K., et al.

Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 Kasım 2020, cilt.72 Sürdürülebilir Kalkınma

SIGNIFICANT KNOWLEDGE GAP ABOUT NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN REAL-WORLD PRACTICES: A GLOBAL SURVEY OF HEPATOLOGISTS, GASTROENTEROLOGISTS, ENDOCRINOLOGISTS AND PRIMARY CARE PHYSICIANS

Younossi Z. M., Takahashi H., Eguchi Y., YILMAZ Y., El Kassas M., Zheng M., et al.

Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 Kasım 2020, cilt.72

Comparison of clinical and histological characteristics of biopsyproven non-alcoholic fatty liver patients with and without type 2 diabetes mellitus: 10 years of experience from a single tertiary care center

APASL 2020 Bali - 29th Annual Conference Asian Pacific Association for the Study of the Liver, Balvi, Letonya, 4 - 08 Mart 2020, cilt.14, ss.1-470 Sürdürülebilir Kalkınma

THE IMPACT OF FATIGUE ON PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY (GLR)

Digestive Disease Week, Amerika Birleşik Devletleri, 23 Ocak 2020, cilt.158, ss.1269

CLINICAL AND PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS (HBV) INFECTION SEEN IN REAL-WORLD PRACTICES ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Amerika Birleşik Devletleri, 08 Kasım 2019, cilt.70, ss.577-578 Sürdürülebilir Kalkınma

SEVERE IMPAIRMENT OF PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION SEEN IN REAL-WORLD PRACTICES ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Amerika Birleşik Devletleri, 08 Kasım 2019, cilt.359 Sürdürülebilir Kalkınma

CAN ADVANCED FIBROSIS RELIABLY EXCLUDED BY SIMPLE NON-INVASIVE FIBROSIS SCORING SYSTEMS?: PERFORMANCE OF FIB-4 AND NFS IN A BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE SAMPLE

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Amerika Birleşik Devletleri, 08 Kasım 2019, cilt.70, ss.1053-1054

CLINICAL AND PATIENT-REPORTED OUTCOMES DATA FOR PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON-ALCOHOLIC STEATOHEPATITIS (NASH) ACROSS THE WORLD: DATA FROM THE GLOBAL NASH REGISTRY

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Amerika Birleşik Devletleri, 08 Kasım 2019

DIFFERENCES IN THE CLINICAL PROFILE OF THE MOST COMMON CAUSES OF CHRONIC LIVER DISEASE (CLD) ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Amerika Birleşik Devletleri, 08 Kasım 2019, cilt.70, ss.463-465

USEFULNESS OF ENDOSCOPIC ULTRASONOGRAPHY ELASTOGRAPHY (EUS-E) TO MEASURE LIVER STIFFNESS

Duman D. G., Alahdab Y., Demirtas C. O., YILMAZ Y., GÜNDÜZ F.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70

THE UTILITY OF NONINVASIVE SCORES IN ASSESSING THE ADVANCED HEPATIC FIBROSIS IN TYPE 2 DIABETIC PATIENTS WITH BIOPSY PROVEN NONALCOHOLIC FATTY LIVER DISEASE

Alkayyali T., Quatranji L., Kaya E., Bakir A., YILMAZ Y.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70 Sürdürülebilir Kalkınma

ARTERIAL STIFFNESS IS INDEPENDENTLY ASSOCIATED WITH LIVER STIFFNESS IN BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE: A TRANSIENT ELASTOGRAPHY STUDY

Bilgin B. O., SÜNBÜL M., Kani H. T., Demirtas C. O., KEKLİKKIRAN Ç., YILMAZ Y.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70

lLver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease

Sun D., Fun Zhou Y., Kani H. T., Chen Fei Z., Pei Wu Z., Hong Lei M., et al.

EASL 2019, Paris, Fransa, 14 Nisan 2019

ILver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease

Sun D. Q., Ye F., Haluk Tarik K., Zheng C., Zhu P., Ma H., et al.

International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Avusturya, 10 - 14 Nisan 2019, cilt.70

Translating NAFLD AASLD data to local practice

AASLD TASL Regional Connect Meeting, İstanbul, Türkiye, 15 - 16 Mart 2019

Nonalcoholic Fatty Liver Disease(NAFLD) and Alcoholic Fatty Lİver Disease(AFLD): The impact of Alcohol Comsumpt,on and Metabolic Syndrome on Mortality

Younossi Z., Stepanova M., Ong J., Yılmaz Y., Duseja A., Eguchi Y., et al.

THE AASLD LIVER MEETING, South-Carolina, Amerika Birleşik Devletleri, 9 - 13 Kasım 2018

Noninvazif Fibrozis ve Yağlanma Ölçümü:Fibroscan/CAP

4. Azerbaycan-Türkiye Ortak Hepatoloji Kursu, Baku, Azerbaycan, 06 Ekim 2018

Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcoholic Fatty Liver Disease (AFLD): The Impact of Alcohol Consumption and Metabolic Syndrome on Mortality

Younossi Z. M., Stepanova M., Ong J., YILMAZ Y., Duseja A. K., Eguchi Y., et al.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Kostarika, 9 - 13 Kasım 2018, cilt.68

Non-alcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma listed for liver transplantation in United States: data from the Scientific Registry of Transplant Recipients

Younossi Z., Stepanova M., Ong J., Jacobson I., Bugianesi E., Duseja A., et al.

Joint International Congress of ILTS, ELITA and LICAGE, Lisbon, Portekiz, 23 - 26 Mayıs 2018, cilt.102, ss.304-305

Transient elastography with controlled attenuation parameterin the assessment of hepatic steatosis and significant liver fibrosisin patients with scleroderma

Yılmaz Y., Kani H. T., Şahinkaya Y., Mursaloğlu H. H., Aziziy M., İnanç G. N., et al.

27th Annual Conference of APASL, Dilli, Hindistan, 14 - 18 Mart 2018, cilt.12, ss.378

Tanıdan tedaviye alkole bağlı olmayan yağlı karaciğer hastalığı

Baku 2018 Hepatoloji Sempozyumu, Baku, Azerbaycan, 21 Ocak 2018

Karaciğer fibrozisinin değerlendirilmesinde elastografinin rolü

Baku 2018 Hepatoloji Sempozyumu, Baku, Azerbaycan, 21 Ocak 2018

Klinik pratikte transiyent elastografi kullanımı

Baku 2018 Hepatoloji Sempozyumu, Baku, Azerbaycan, 21 Ocak 2018

Preliminary evidence of an association between mtDNA D-loop polymorphisms and the clinicopathological features of nonalcoholic steatohepatitis

Hasturk B., Yılmaz Y., Eren F.

68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Washington, Kiribati, 20 - 24 Ekim 2017, cilt.66

Nonalcoholic steatohepatitis: modulation of histological phenotype by the missense Thr174Met (rs4762) polymorphism of the angiotensinogen (AGT) gene

EREN F., Balcilar H., Yilmaz D., Toker T., YILMAZ Y., Hasturk B.

68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Washington, Kiribati, 20 - 24 Ekim 2017, cilt.66

Mitochondrial DNA control region nucleotide variations in non-alcoholic steatohepatitis

Hasturk B., Yılmaz Y., Eren F.

European Biotechnology Congress, Dubrovnik, Hırvatistan, 25 - 27 Mayıs 2017, cilt.256

The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study

UYGUN A., öztürk k., demirci h., öztuna a., EREN F., KOZAN S., et al.

JOURNAL OF HEPATOLOGY, Amsterdam, Hollanda, 19 - 23 Nisan 2017, cilt.66, ss.148

Prevalence of fatty liver in inflammatory bowel disease : a transient elastography study on the basis of a controlled attenuation parameter.

YILMAZ Y., KANİ H. T.

5th Annual Meeting of the Asian Organization for Crohn’s and Colitis, Seul, Güney Kore, 15 - 17 Haziran 2017

Prevalence of Fatty Liver in IBD: ATransient Elastography Study on theBasis of a Controlled AttenuationParameter

Kani H. T., Demirtas I., Yılmaz Y.

The 5th Annual Meeting of Asian Organization for Crohn’s Colitis, Seoul, Güney Kore, 15 - 17 Haziran 2017, ss.235-236

NAFLD: Yeni ne var?

11. Ulusal Hepatoloji Kongresi, Antalya, Türkiye, 17 - 21 Mayıs 2017

Hepatit C Tedavilerinin İlaç Etkileşimleri

Sağlık Bilimleri Üniversitesi Gastroenteroloji Günleri, İstanbul, Türkiye, 28 - 29 Nisan 2017 Sürdürülebilir Kalkınma

Marmara Üniversitesi Tıp Fakültesi Harvoni Deneyimi

Sağlık Bilimleri Üniversitesi Gastroenteroloji Günleri, İstanbul, Türkiye, 28 - 29 Nisan 2017

NASH'te yeni ne var?

14. Ulusal Hepatogastroenteroloji Kongresi, Antalya, Türkiye, 5 - 08 Nisan 2017

Yüzyılın Epidemisi Alkol Dışı Karaciğer Yağlanması Hastalığı

33. Ulusal Gastroenteroloji Haftası, Antalya, Türkiye, 22 - 27 Aralık 2016

COMPARİSİON OF DOPPLER ULTRASOUND AND TRANSİENT ELASTOGRAPHY FOR DİAGNOSİS OF SİGNİFİCANT FİBROSİS İN NONALCOHOLİC STEATOHEPATİT

ERGELEN R., YILMAZ Y., ASADOV R., CELİKEL Ç., AKIN H., BUGDAYCI O., et al.

ESGAR, 14 - 16 Aralık 2016

Obezite ve yağlı karaciğer

7. Ulusal Obezite Kongresi, İstanbul, Türkiye, 8 - 11 Aralık 2016 Sürdürülebilir Kalkınma

Sülfasalazin kullanımı sonrası gelişen Dress sendromu Olgu sunumu

DURĞAY M., AYKUT U. E., ÖZEN ALAHDAB Y., YILMAZ Y., DEMİR O.

33. Ulusal Gastroenteroloji Haftası, Antalya, Türkiye, 22 - 27 Kasım 2016

İrritabl barsak sendromlu hastalarda yüksek laktoz intolerans sıklığı

hasanov r., ÖZEN ALAHDAB Y., EREN F., GÜNDÜZ F., YILMAZ Y., AYKUT U. E.

33.Ulusal gastroenetroloji haftası, Türkiye, 22 - 27 Kasım 2016

Türk toplumunda alkolik olmayan yağlı karaciğer hastalığının genetik polimorfizm ile ilişkisi çok merkezli kontrollü çalışma

UYGUN A., öztürk k., DEMİRCİ H., öztuna a., EREN F., YILMAZ Y., et al.

33.Ulusal gastronetroloji haftası, Antalya, Türkiye, 22 - 27 Kasım 2016

Two atypical forms of Nonalcoholic fatty liver disease NAFLD without metabolic syndrome and Lean NAFLD

APASL Single Topic Conference, İstanbul, Türkiye, 22 - 24 Eylül 2016

MT ND5 gene variants have both protective and risk factor for inflammatory bowel disease

Eren F., Safarova C., Gündüz F., Özen Alahdab Y., Kurt R., Yılmaz Y., et al.

The 4th Annual Meeting of Asian Organization for Crohn's & Colitis, Kyoto, Japonya, 7 - 09 Temmuz 2016

Bactericidal permeability increasing protein has no effect on remission of ulcerative colitis

EREN F., eroğlu k., Banzragch M., GÜNDÜZ F., ÖZEN ALAHDAB Y., KURT R., et al.

The 4th Annual Meeting of Asian Organization for Crohn's & Colitis, Kyoto, Japonya, 7 - 09 Temmuz 2016

Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis

ERGELEN R., YILMAZ Y., ASADOV R., ÇELİKEL Ç., AKIN H., BUGDAYCI O., et al.

European Society of Gastrointestinal and Abdominal Radiology, 14 - 17 Haziran 2016

Yağlı Karaciğerde Yeni İlaç Tedavileri

Klinik Gastroenteroloji Toplantısı-5, İstanbul, Türkiye, 02 Haziran 2016

Kronik Viral Hepatitlerde Non İnvazif Yöntemle Fibrozis Belirleme Algoritmleri

Hepatit B Enfeksiyonu Akademisi, Çanakkale, Türkiye, 28 Mayıs 2016

Controlled attenuation parameter and liver stiffness measurements by fibroscan for the detection of non alcoholic fatty liver disease in patients with type 2 diabetes results from a pilot study

DURĞAY M., DEYNELİ O., YILMAZ Y.

EASL monothematic conference 2016, Riga, Letonya, 12 - 14 Mayıs 2016 Sürdürülebilir Kalkınma

Karaciğer Hasarının Değerlendirilmesi Non İnvazif Testlere Algoritmik Yaklaşım

XIII. Ulusal Viral Hepatit Kongresi, Antalya, Türkiye, 17 - 20 Mart 2016

Alkol Dışı Yağlı Karaciğer Hastalığında Yeni Ne Var

TKAD Mezuniyet Sonrası Eğitim Sempozyumu: Karaciğerde Çok Yenilik Var:AASLD 2015’den Süzülenler, İstanbul, Türkiye, 13 Ocak 2016

Karaciğer Fibrozisinde Yeni Non İnvaziv Yöntem ELF Test

DURUSOY S. S., ÖZDEMİR F. T., ÖZDOĞAN O. C., RAHMİ A., YILMAZ Y., YEĞİN E. G., et al.

32. Ulusal Gastroenteroloji Haftası, Türkiye, 25 - 29 Kasım 2015

Diyabetik Hastalarda Nonalkolik Yağlı Karaciğer Hastalığının ve Fibrozisin Fibroscan Aracılı CAP ve Karaciğer Sertlik Ölçümü ile Prospektif Taranması Ön Bulgularımız

DURĞAY M., DEYNELİ O., YILMAZ Y.

32. Ulusal Gastroenteroloji Haftası, Türkiye, 25 - 29 Kasım 2015 Sürdürülebilir Kalkınma

Does Helicobacter pylori Infection Influences the Complication rate After Sleeve Gastrectomy From an Endemic Region

AKYÜZ Ü., ALTUN H., BURÇİN B., YILMAZ Y., DERYA U.

32. Ulusal Gastroenteroloji Haftası, Türkiye, 25 - 29 Kasım 2015

Ülseratif Kolitin ÜK Hastalık Aktivitesi Bakterisidal Permeabilite Arttırıcı Protein BPI Düzeyi ile İlişkilidir

EREN F., EROĞLU K., MUNKHTSETSEG B., ALAHDAB Y. Ö., KURT R., YILMAZ Y., et al.

32. Ulusal Gastroenteroloji Haftası, Türkiye, 25 - 29 Kasım 2015

NASH Pategenez ve Tedavisinde Yeni Bir Şey Var Mı

32.Ulusal Gastroenteroloji Haftası, Antalya, Türkiye, 25 - 29 Kasım 2015

Ülseratif kolitin hastalık aktivitesi bakterisidal permeabilite arttırıcı protein BPI düzeyi ile ilişkilidir

EREN F., eroğlu k., banzragch m., GÜNDÜZ F., ÖZEN ALAHDAB Y., KURT R., et al.

32. Ulusal Gastroenetroloji Haftası, Türkiye, 25 - 29 Kasım 2015

NAFLD in absence of Metabolic Syndrome

FRONTIERS IN HEPATOLOGY Non-alcoholic Fatty Liver Disease & the Metabolic Syndrome – Key questions on disease consequences and treatment –, Londrina, Brezilya, 24 Kasım 2015

Latent tüberküloz tanısında interferon gamma salınım testi ile tüberkülin deri testinin karşılaştırılması

ÖZEN ALAHDAB Y., Kedrah A. E., GÜNDÜZ F., YÖNAL O., YILMAZ Y., ALAHDAB H., et al.

BUHASDER 6.Tepecik Enfeksiyon Günleri Sempozyumu, Muğla, Türkiye, 4 - 08 Kasım 2015 Sürdürülebilir Kalkınma

Nonalkolik Yağlı Karaciğerli Hastalarda İleri Evre Fibrozisin Saptanmasında Noninvazif Yeni Bir Yöntem Olan Fibrometer VCTE nin Tanısal Performansı

DİNÇSES E., YILMAZ Y.

32. Ulusal Gastroenteroloji Haftası, Türkiye, 25 - 29 Kasım 2015, cilt.26, ss.21

Aktif Kahverengi Yağ Dokusu Varlığı Yağlı Karaciğer Hastalığı Gelişimini Önlüyor Olabilir

Salih Ö., Tunç Ö., YILMAZ Y., TUROĞLU H. T., İMERYÜZ N.

32. Ulusal Gastroenteroloji Haftası, Türkiye, 25 - 29 Kasım 2015, cilt.26, ss.43-44

Non alcoholic steatohepatitis score is an independent predictor of right ventricular dysfunction in patients with non alcoholic fatty liver disease

SÜNBÜL M., KIVRAK T., DURMUŞ E., AKIN H., AYDIN Y., ERGELEN R., et al.

31. TURKISH CARDIOLOGY CONGRESS WITH INTERNATIONAL PARTICIPATION, 22 - 25 Ekim 2015

Can FibroMeter VCTE (TM) be useful for detecting hepatic fibrosis in patients with non-alcoholic fatty liver disease?

Dincses E., YILMAZ Y.

66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Kostarika, 13 - 17 Kasım 2015, cilt.62

Can FibroMeter VCTE be useful for detecting hepatic fibrosis in patients with non alcoholic fatty liver disease

DİNÇSES E., YILMAZ Y.

The AASLD Liver Meeting 2015, San-Francisco, Kostarika, 13 - 17 Kasım 2015, cilt.62, ss.1270

Yeni Antikoagülanlar İşlem öncesi ve sonrası yaklaşım

3.Gastrointestinal Endoskopi Günleri, İstanbul, Türkiye, 8 - 09 Mayıs 2015

Characterization of Lean Patients With Nonalcoholic Fatty Liver Disease Potential Role of High Hemoglobin Levels

AKYÜZ Ü., YEŞİL A., YILMAZ Y.

46th Annual Digestive Disease Week (DDW), Washington, Kiribati, 16 - 19 Mayıs 2015, cilt.148, ss.1058

Noninvasive tests in the diagnosis of Non Alcoholic Fatty Liver Disease

The 24th Conference of the Asian Pacific Association for the Study of Liver (APASL), İstanbul, Türkiye, 12 - 15 Mart 2015

Yağlı Karaciğer Non alkolik Steatohepatit ve Alkolik Steatohepatit

Uludağ İç Hastalıkları Kış Kongresi, Bursa, Türkiye, 08 Mart 2015

Hepatoselüler Karsinoma Karsinogenezde endokrin metabolik mekanizmalar

13. Hepatoloji Sempozyumu, Ankara, Türkiye, 17 Ocak 2015

Barsak karaciğeri nasıl etkiler

31. Ulusal Gastroenteroloji Haftası, Antalya, Türkiye, 24 - 28 Kasım 2014

Otoimmün hepatit ilaç hepatotoksisitesi yağlı karaciğer ve hepatitte yaklaşım ilaç seçimi ve izlem

A’dan Z’ye Psöriazis Toplantısı, İstanbul, Türkiye, 08 Kasım 2014 Sürdürülebilir Kalkınma

Klinik Araştırma Planlaması

11. Ulusal HEBİPA Kongresi, Kıbrıs (Kktc), 24 - 28 Eylül 2014

Alkol Dışı Yağlı Karaciğer Hastalığı

1. TÜRKİYE-AZERBAYCAN ORTAK HEPATOLOJİ KURSU, İstanbul, Türkiye, 18 - 19 Eylül 2014

Biodegradable Stentler

Türk Gastroenteroloji Derneği İstanbul Şubesi Mezuniyet Sonrası Eğitim Toplantısı, İstanbul, Türkiye, 25 Haziran 2014

Fibrokistik Karaciğer Hastalıkları

Türk Karaciğer Araştırmaları Derneği Mezuniyet Sonrası Eğitim Toplantısı, İstanbul, Türkiye, 13 Haziran 2014

KC biyopsi Fibroscan uygulamaları

AYGÜN C., YILMAZ Y.

5. Hepatoloji Okulu, Kocaeli, Türkiye, 30 Mayıs - 01 Haziran 2014

Karaciğer Transplantasyonlu Hastalarda Metabolik Komplikasyonlar ve Sorunların Yönetimi

Organ Nakilleri Bilinçlendirme ve Geliştirme DerneğiKaraciğer Nakli Mezuniyet Sonrası Eğitim Kursu 1, İstanbul, Türkiye, 24 Mayıs 2014

Alkol Dışı Yağlı Karaciğer Hastalıkları

İSTAHED Kongresi Viral Hepatitler ve Diğer Hepatobilier hastalıklarda Klinik Yaklaşım Kursu, Antalya, Türkiye, 10 Mayıs 2014

Nonalkolik yağlı karaciğer Nonalkolik steatohepatit

Türk Karaciğer Vakfı Mezuniyet Sonrası Eğitim Toplantıları, İstanbul, Türkiye, 29 Mart 2014

Erişkinde Yağlı Karaciğer Hastalığı ve Yönetimi Yenilik var mı

Karaciğer Hastalıkları ve Transplantasyonu Güncelleme Toplantısı, İstanbul, Türkiye, 01 Mart 2014

Are patients with biopsy proven non alcoholic fatty liver disease at increased risk of asthma Results from a Turkish cross sectional study

TAŞLI B., YILMAZ Y.

The Asian Pacific Society of Respirology 19th Congress, Balvi, Letonya, 13 - 16 Kasım 2014, cilt.19, ss.173-203

Fibroscan aracılı CAP kronik karaciğer hastalıklarında yağlanmanın şiddetini hastalık etyolojisinden ve fibrozisten bağımsız olarak doğru tahmin eder

YILMAZ Y., YEŞİL A., GERİN F., ERGELEN R., AKIN H., ÇELİKEL Ç., et al.

30. Ulusal Gastroenteroloji Haftası, Türkiye, 11 - 15 Ekim 2013

CAP yöntemli Fibroscan ile karaciğer yağlanmasının kantitatif değerlendirilmesi Karaciğer biyopsisi ile karşılaştırmalı prospektif çalışma

YILMAZ Y., YESIL A., GERİN F., ERGELEN R., AKIN H., ÇELİKEL Ç., et al.

30. Ulusal Gastroenteroloji Haftası, Türkiye, 11 - 15 Ekim 2013

Evaluation of gallbladder kinetics in patients with nonalcoholic fatty liver disease

Colak Y., Bozbey G., Senates E., Doganay L., Coskunpinar E., Ozturk O., et al.

64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 Kasım 2013, cilt.58

NAFLD da Metformin Hiç Vermeyelim mi

10.Ulusal Hepato Gastroenteroloji Kongresi, Magosa, Kıbrıs (Kktc), 25 - 29 Eylül 2013

Mikrobiyota ve Nonalkolik Yağlı Karaciğer Hastalığı